Business Brief -- Bolar Pharmaceutical Co.:
   Settlement Is Set Involving
   Sales of SmithKline Stock
In 1990, Bolar, a Copiague, N.Y., generic drug concern,
was implicated in selling some mislabeled and adulterated
generic drugs. Last year the company settled for $40 million
a major lawsuit by SmithKline Beecham over Bolar's efforts to
market a generic version of SmithKline's blood-pressure
medicine Dyazide. SmithKline Beecham Inc.'s parent is
SmithKline Beecham PLC, a London-based pharmaceutical
concern.